EGFR and colorectal carcinoma: For example, anti-epidermal growth factor receptor antibodies should not be administered to colorectal carcinoma patients with KRAS mutations in codons 12 or 13 [21], although improved cost-effectiveness can be demonstrated for the remaining subset of patients.